GDNF gene therapy (Ceregene)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameGDNF gene therapy (Ceregene)
Drug Alias NameAAV-GDNF gene therapy (Ceregene)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionGlial cell line-derived neurotrophic factors stimulants
TargetsGlial cell line-derived neurotrophic factors
Therapy Area/IndicationsParkinson DiseaseHuntington Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCeregene Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCeregene Inc
Active IndicationsN/A
Inactive IndicationsParkinson DiseaseHuntington Disease

Other Information

ATC CodeN/A
Related LinksN/A